Phathom Pharmaceuticals is developing a next-generation stomach acid reducer that would represent the first new mechanism of action in the space in 30 years. Phathom's drug, vonoprazan, has ...

--Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the U.S. commercial ...

Vonoprazan is a potassium-competing acid blocker and, at present, has been approved in the form of 10 mg and 20 mg tablets in the treatment of all grades of erosive esophagitis. Transcript This ...

Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial – An AGA Reading Room selection October 24, 2022 ...

In May, FDA approved Voquenza (vonoprazan fumarate), in combination with anti-biotics, for H.pylori infection. In March, Phathom Pharmaceuticals submitted an NDA to FDA for the use of vonoprazan ...

Among those on vonoprazan throughout the study, mean percentages of 24-hour heartburn-free days were 62.6% for the 10 mg dose (n = 247), and 60.7% for the 20 mg dose (n = 235).

For the maintenance phase of the trial, vonoprazan 10 mg was found to be superior to lansoprazole 15 mg in consistent healing at 6 months. In the healing phase, the adverse events (AEs) for vonoprazan ...

For the overall study population, the H. pylori eradication rate was 80.8% with the vonoprazan-based triplet and 77.2% with the doublet versus 68.5% with lansoprazole triple therapy, while those ...

A triple therapy of vonoprazan, amoxicillin and bismuth potassium citrate achieved an eradication rate of just over 90%, similar to that of the standard quadruple therapy, in patients with ...

The oral potassium-competitive acid blocker vonoprazan was noninferior and superior to the proton pump inhibitor lansoprazole for erosive esophagitis in a phase 3 trial.

Vonoprazan was associated with a significantly greater percentage of 24-hour heartburn free days in patients with symptomatic nonerosive gastroesophageal reflux disease (NERD) compared with ...

FLORHAM PARK, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...